

Fabrizio Bossa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4559072/publications.pdf>

Version: 2024-02-01

117
papers

4,572
citations

109321

35
h-index

106344

65
g-index

121
all docs

121
docs citations

121
times ranked

6844
citing authors

#	ARTICLE	IF	CITATIONS
1	Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn's Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1104-1113.	27.0	366
2	Ulcerative colitis risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. <i>Nature Genetics</i> , 2009, 41, 216-220.	21.4	364
3	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	4.4	316
4	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , 2020, 69, 1213-1217.	12.1	283
5	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	1.3	251
6	ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	2.9	139
7	Combination Immunomodulator and Antibiotic Treatment in Patients With Inflammatory Bowel Disease and <i>Clostridium difficile</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 981-987.	4.4	128
8	Multidrug resistance 1 gene in inflammatory bowel disease: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2006, 12, 3636.	3.3	125
9	The PROSIT-BIO Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 233-243.	1.9	116
10	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	1.3	114
11	Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. <i>American Journal of Gastroenterology</i> , 2007, 102, 601-608.	0.4	95
12	Randomised controlled trial of mesalazine in IBS. <i>Gut</i> , 2016, 65, 82-90.	12.1	91
13	Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 829-843.	1.3	80
14	Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 194-198.	1.3	78
15	Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2014, 46, 969-973.	0.9	78
16	Polymorphisms of Tumor Necrosis Factor- α but Not <i>MDR1</i> Influence Response to Medical Therapy in Pediatric Onset Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2007, 44, 171-179.	1.8	76
17	Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study. <i>Digestive and Liver Disease</i> , 2005, 37, 577-583.	0.9	75
18	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. <i>Genes and Immunity</i> , 2012, 13, 461-468.	4.1	75

#	ARTICLE	IF	CITATIONS
19	Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. PLoS ONE, 2013, 8, e62144.	2.5	75
20	Adalimumab in active ulcerative colitis: A "real-life" observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.9	72
21	Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study. American Journal of Gastroenterology, 2008, 103, 2509-2516.	0.4	66
22	Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. World Journal of Gastroenterology, 2008, 14, 4643.	3.3	66
23	Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Alimentary Pharmacology and Therapeutics, 2005, 22, 1129-1138.	3.7	60
24	Variants of OCTN1 "2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 23, 497-506.	3.7	57
25	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. Journal of Crohn's and Colitis, 2014, 8, 1217-1221.	1.3	53
26	Investigation of Multiple Susceptibility Loci for Inflammatory Bowel Disease in an Italian Cohort of Patients. PLoS ONE, 2011, 6, e22688.	2.5	53
27	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases, 2019, 25, 568-579.	1.9	51
28	Systematic analysis of circadian genes using genome-wide cDNA microarrays in the inflammatory bowel disease transcriptome. Chronobiology International, 2015, 32, 903-916.	2.0	50
29	Detection of abnormal lesions recorded by capsule endoscopy: A prospective study comparing endoscopist's and nurse's accuracy. Digestive and Liver Disease, 2006, 38, 599-602.	0.9	44
30	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.9	42
31	Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. Alimentary Pharmacology and Therapeutics, 2007, 26, 737-745.	3.7	41
32	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. Digestive and Liver Disease, 2014, 46, 963-968.	0.9	39
33	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2016, 14, 1426-1432.e1.	4.4	39
34	Association Study of a Polymorphism in Clock Gene PERIOD3 and Risk of Inflammatory Bowel Disease. Chronobiology International, 2012, 29, 994-1003.	2.0	38
35	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.9	36
36	Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGR11A genes in inflammatory bowel disease: A meta-analysis. Inflammatory Bowel Diseases, 2007, 13, 1212-1219.	1.9	35

#	ARTICLE	IF	CITATIONS
37	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". Digestive and Liver Disease, 2017, 49, 17-23.	0.9	35
38	The association of <i>MYO9B</i> gene in Italian patients with inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2008, 27, 241-248.	3.7	31
39	Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant irritable bowel syndrome and functional constipation. Neurogastroenterology and Motility, 2016, 28, 581-591.	3.0	30
40	COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association. Inflammatory Bowel Diseases, 2021, .	1.9	28
41	Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. Journal of Crohn's and Colitis, 2014, 8, 1642-1652.	1.3	27
42	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. Journal of Crohn's and Colitis, 2016, 11, jjw181.	1.3	27
43	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. Clinical and Experimental Immunology, 2019, 196, 123-138.	2.6	27
44	False-positive results of SARS-CoV-2 IgM/IgG antibody tests in sera stored before the 2020 pandemic in Italy. International Journal of Infectious Diseases, 2021, 104, 159-163.	3.3	26
45	The A2518G Polymorphism of Monocyte Chemoattractant Protein-1 Is Associated With Crohn's Disease. American Journal of Gastroenterology, 2010, 105, 1586-1594.	0.4	24
46	Neuroimmune interactions in patients with inflammatory bowel diseases: Disease activity and clinical behavior based on Substance P serum levels. Journal of Crohn's and Colitis, 2012, 6, 563-570.	1.3	23
47	Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia. Scientific Reports, 2016, 6, 31549.	3.3	23
48	Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2010, 16, 1108-1117.	1.9	22
49	Erythrocytes-mediated Delivery of Dexamethasone 21-phosphate in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1.	1.9	22
50	Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	22
51	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease, 2022, 54, 440-451.	0.9	22
52	Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: An IG-IBD study. Journal of Crohn's and Colitis, 2010, 4, 291-300.	1.3	21
53	Enteropathic spondyloarthropathy: A common genetic background with inflammatory bowel disease?. World Journal of Gastroenterology, 2009, 15, 2456.	3.3	21
54	One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opinion on Biological Therapy, 2021, 21, 1483-1489.	3.1	20

#	ARTICLE	IF	CITATIONS
55	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 510-515.	0.9	18
56	Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. <i>Digestive and Liver Disease</i> , 2021, 53, 277-282.	0.9	18
57	Functional Implications of MicroRNAs in Crohn's Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1580.	4.1	17
58	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235.	3.8	16
59	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease "AGED" study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1361-1369.	1.6	14
60	Transperineal ultrasonography: First level exam in IBD patients with perianal disease. <i>Digestive and Liver Disease</i> , 2016, 48, 874-879.	0.9	13
61	Crohn's Disease Localization Displays Different Predisposing Genetic Variants. <i>PLoS ONE</i> , 2017, 12, e0168821.	2.5	13
62	Worse clinical course of disease in Crohn's patients with previous appendectomy. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 623-627.	1.6	12
63	Erythrocytes as a controlled drug delivery system: Clinical evidences. <i>Journal of Controlled Release</i> , 2006, 116, e43-e45.	9.9	12
64	Colorectal cancer and high grade dysplasia complicating ulcerative colitis in Italy. <i>Digestive and Liver Disease</i> , 2003, 35, 628-634.	0.9	11
65	Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1767-1776.	2.3	11
66	microRNA-mRNA network model in patients with achalasia. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13764.	3.0	11
67	Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IGBD study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1432-1441.	3.7	11
68	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 687-694.	1.3	10
69	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. <i>Cells</i> , 2019, 8, 523.	4.1	10
70	Linear IgA bullous dermatosis and Ulcerative colitis treated by proctocolectomy. <i>European Journal of Dermatology</i> , 2009, 19, 651-651.	0.6	10
71	745 Methotrexate for Corticosteroid-Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial. <i>Gastroenterology</i> , 2015, 148, S-140.	1.3	9
72	Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1579-1582.	1.6	9

#	ARTICLE	IF	CITATIONS
73	Impact of genetic polymorphisms on the pathogenesis of idiopathic achalasia: Association with IL33 gene variant. <i>Human Immunology</i> , 2014, 75, 364-369.	2.4	8
74	Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. <i>United European Gastroenterology Journal</i> , 2021, 9, 102-109.	3.8	8
75	Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 201-207.	1.6	8
76	Treatment of steroid-naive ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1449-1460.	1.8	7
77	IL23R, ATG16L1, IRGM, OCTN1, and OCTN2 mRNA expression in inflamed and noninflamed mucosa of IBD patients. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1832-1833.	1.9	7
78	Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1371-1382.	2.3	7
79	Nurse in patients' health status assessment: Data from a pilot study assessing agreement among nurse and gastroenterologist in computing IBD-clinical scores. <i>Digestive and Liver Disease</i> , 2017, 49, 1110-1114.	0.9	7
80	Unmet needs of Italian physicians managing patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2019, 51, 212-217.	0.9	6
81	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e134-e136.	1.9	6
82	Germline Alterations in Patients With IBD-associated Colorectal Cancer. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 447-454.	1.9	6
83	Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2017, 8, 131.	1.1	6
84	439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilar. <i>Gastroenterology</i> , 2016, 150, S92.	1.3	5
85	Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 174-175.	3.7	5
86	Takotsubo Syndrome and Inflammatory Bowel Diseases: Does a Link Exist?. <i>Digestive Diseases</i> , 2020, 38, 204-210.	1.9	5
87	Interobserver agreement of the Paris and simplified classifications of superficial colonic lesions: a Western study. <i>Endoscopy International Open</i> , 2021, 09, E388-E394.	1.8	5
88	Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease. <i>Digestive and Liver Disease</i> , 2019, 51, 804-811.	0.9	3
89	Barriers to anti-TNFalpha prescription among Italian physicians managing inflammatory bowel disease. <i>GastroHep</i> , 2019, 1, 93-99.	0.6	3
90	Accuracy and inter-observer agreement of the nice and kudo classifications of superficial colonic lesions: a comparative study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1561-1568.	2.2	3

#	ARTICLE	IF	CITATIONS
91	New biologics in the management of Crohn's disease: focus on certolizumab pegol. <i>Clinical and Experimental Gastroenterology</i> , 2009, 2, 61-8.	2.3	3
92	PC.01.8 INCREASING INTEROBSERVER AGREEMENT ON IBD ENDOSCOPIC SCORING SYSTEMS: RESULTS FROM THE IGBDENDO EDUCATIONAL PROGRAM. <i>Digestive and Liver Disease</i> , 2014, 46, S4.	0.9	2
93	A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort. <i>Gastroenterology</i> , 2017, 152, S108.	1.3	2
94	Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care. <i>Reviews on Recent Clinical Trials</i> , 2021, 16, 329-334.	0.8	2
95	Inverted colonic diverticulum (ICD): report of two cases and literature review of a not that unusual endoscopic challenge. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101711.	1.5	2
96	How evidence-based are current guidelines for managing patients with peptic ulcer bleeding?. <i>World Journal of Gastrointestinal Surgery</i> , 2010, 2, 9.	1.5	1
97	Long-term remission with adalimumab in steroid-dependent Crohn's disease patients with multiple drug intolerances. <i>Digestive and Liver Disease Supplements</i> , 2010, 4, 7-9.	0.2	1
98	Dissecting the mucosal expression of human leucine-rich repeat family genes in inflammatory bowel disease patients. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1834-1835.	1.9	1
99	P.06.23 INFlixIMAB IN STEROID-DEPENDENT ULCERATIVE COLITIS: LACK OF PREDICTIVE FACTORS FOR RESPONSE IN A LARGE MULTICENTER SERIES. <i>Digestive and Liver Disease</i> , 2014, 46, S78.	0.9	1
100	685 Risk Factor Analysis for Therapy Related Adverse Events and Infections in Elder Patients With Inflammatory Bowel Disease; An Analysis From the iG-IBD Aged Study. <i>Gastroenterology</i> , 2015, 148, S-133.	1.3	1
101	P.07.14 INTER-OBSERVER AGREEMENT OF ULCERATIVE COLITIS "EXTENDED MAYO ENDOSCOPIC SCORE (EMES)" WITHIN A MULTICENTER INFLAMMATORY BOWEL DISEASE (IBD) TEAM WORK. <i>Digestive and Liver Disease</i> , 2019, 51, e227-e228.	0.9	1
102	Transabdominal ultrasound-guided pancreatic biopsy: a neglected but safe, effective and inexpensive procedure that needs to be re-juvinalized. <i>Journal of Ultrasound</i> , 2021, 24, 175-182.	1.3	1
103	Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 11356-11364.	0.7	1
104	Presentation of colorectal cancer in patients with ulcerative colitis: A GISC-GTSMII multicenter investigation. <i>Gastroenterology</i> , 2000, 118, A1408.	1.3	0
105	The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases. <i>Digestive and Liver Disease Supplements</i> , 2010, 4, 1-3.	0.2	0
106	Dissection of the Crohn's Disease Transcriptome of 71 Loci Using Genome-Wide Microarrays. <i>Gastroenterology</i> , 2011, 140, S-272-S-273.	1.3	0
107	Sa1221 Increasing Interobserver Agreement on IBD Endoscopic Scoring Systems: Results From the IGBDEndo Educational Program. <i>Gastroenterology</i> , 2014, 146, S-234.	1.3	0
108	Tu1156 Genome-Wide Expression Profiling of Idiopathic Achalasia Patients. <i>Gastroenterology</i> , 2015, 148, S-805-S-806.	1.3	0

#	ARTICLE	IF	CITATIONS
109	Su1073 The SOLE Survey: Disease Related Concerns of a Large Cohort of Italian Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2015, 148, S-400.	1.3	0
110	Whole Exome Sequencing of very early onset ulcerative colitis patients identifies new variants in candidate genes. <i>Digestive and Liver Disease</i> , 2015, 47, e257-e258.	0.9	0
111	Tu1938 Endoscopic Training Leads to a Significant Increase in Agreement of Endoscopic Scoring for Inflammatory Bowel Disease (IBD): Final Results of the Igbdendo Educational Project. <i>Gastroenterology</i> , 2016, 150, S983-S984.	1.3	0
112	19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study. <i>Gastroenterology</i> , 2016, 150, S6.	1.3	0
113	OC.11.7 MOTIVATIONAL INTERVIEWING IN OUTPATIENTS COUNSELLING: DATA FROM A LARGE CASE-CONTROL STUDY IN INFLAMMATORY BOWEL DISEASE PATIENTS. <i>Digestive and Liver Disease</i> , 2016, 48, e113-e114.	0.9	0
114	Addendum: Palmieri, O. et al. Functional Implications of MicroRNAs in Crohn's Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling. <i>Int. J. Mol. Sci.</i> 2017, 18, 1580. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2113.	4.1	0
115	P.02.10 REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). <i>Digestive and Liver Disease</i> , 2018, 50, e136.	0.9	0
116	P.02.16 ROLE OF ABDOMINAL AND BOWEL ULTRASOUND IN LYNCH SYNDROME, FAMILIAL ADENOMATOUS POLYPOSIS AND OTHER MINOR HEREDITARY SYNDROMES. <i>Digestive and Liver Disease</i> , 2019, 51, e154-e155.	0.9	0
117	P.07.24 AZATHIOPRINE VS MESALAMINE FOR PREVENTION OF POST-OPERATIVE CLINICAL RELAPSE IN CROHN'S DISEASE PATIENTS WITH SEVERE ENDOSCOPIC RECURRENCE: DATA ON EFFICACY AND SAFETY FROM AN IG-IBD MULTICENTER RANDOMIZED DOUBLE-BLIND DOUBLE-DUMMY TRIAL. <i>Digestive and Liver Disease</i> , 2019, 51, e232.	0.9	0